Last reviewed · How we verify
NCT06627270
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Phase 2 trial testing Metronidazole in Oral Squamous Cell Carcinoma in 30 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Case Comprehensive Cancer Center |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 11 March 2025 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Metronidazole (METRONIDAZOLE) — full drug profile →
- Chlorhexidine (CHLORHEXIDINE) — full drug profile →
Conditions studied
- Oral Squamous Cell Carcinoma — all drugs for Oral Squamous Cell Carcinoma →
- Oral Cancer — all drugs for Oral Cancer →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Head and Neck Carcinoma — all drugs for Head and Neck Carcinoma →
Sponsor
Case Comprehensive Cancer Center — full company profile →
Who can join
18 and older, any sex, with Oral Squamous Cell Carcinoma or Oral Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Microbiota in cancer: current understandings and future perspectives.
Yao Y, Zhu Y, Chen K, Chen J, et al · · 2026 · cited 2× · PMID 41629271 · DOI 10.1038/s41392-025-02335-3 -
Intratumoral bacteria are immunosuppressive and promote immunotherapy resistance in head and neck squamous cell carcinoma.
Silver NL, Dai J, Kerr TD, Altemus J, et al · · 2026 · cited 2× · PMID 41482523 · DOI 10.1038/s43018-025-01067-1 -
Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.
Jiang X, Zhang C, Cao S, Peng Y, et al · · 2026 · PMID 42180532 · DOI 10.1016/j.apsb.2026.03.022 -
Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.
Yu Y, Guo Z, Luo Z, Dian Y, et al · · 2026 · PMID 42171956 · DOI 10.1186/s43556-026-00473-w
Verify or expand the search:
- PubMed search for NCT06627270
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Metronidazole
Trials testing the same drug.
- NCT07180615 — Gut Decolonisation With Neomycin/Metronidazole or Rifaximin Before Colon Surgery · Phase 4 · not yet recruiting
- NCT07492134 — APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) · Phase 2 · not yet recruiting
- NCT06616597 — Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Meta · Phase 2 · recruiting
- NCT06798415 — Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis · Phase 2 · recruiting
- NCT06387147 — ORal Antibiotics in Acute Mesenteric Ischemia · Phase 3 · recruiting
Other recruiting trials for Oral Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07063212 — A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC) · Phase 2 · recruiting
- NCT06055868 — People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity · recruiting
- NCT06321003 — SYsteMatical Trained learnIng aLgorithms for Oral carcInogenesiS Interpretation by Optical Coherence Tomography · recruiting
- NCT06258811 — Neoadjuvant Immunochemotherapy for LAOSCC · Phase 3 · recruiting
- NCT05798793 — Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma · Phase 3 · recruiting
Other Case Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
- NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
- NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
- NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
- NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06627270 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
- Last refreshed: 5 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06627270.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing